Novo Ventures’ Lüneborg joins Forbion
Nallicheri ascends to CEO at EQRx, plus: Hummingbird’s new CFO, Acadia, Pillar, Ribon and more
Nanna Lüneborg joined Forbion as general partner to work on the €360 million ($425 million) Forbion Growth Opportunities Fund from the firm’s headquarters in Naarden, The Netherlands. Lüneborg was a partner at Novo Ventures for nine years, where she was involved in growth-stage investments, including investments she led in NBE Therapeutics GmbH, Orphazyme A/S (NASDAQ:ORPH; CSE:ORPHA), ObsEva S.A. (NASDAQ:OBSV; SIX:OBSN) and Numab Therapeutics AG, in which Forbion Growth Opportunities Fund is an investor.
Melanie Nallicheri became CEO at EQRx Inc. succeeding Alexis Borisy, as previously announced. Nallicheri joined in 2020 as president and COO, before which she was CBO and head of biopharma at the Foundation Medicine Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY)...